Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial

[1]  D. Gleason,et al.  PREDICTION OF PROGNOSIS FOR PROSTATIC ADENOCARCINOMA BY COMBINED HISTOLOGICAL GRADING AND CLINICAL STAGING , 2017, The Journal of urology.

[2]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[3]  L. Beckman,et al.  Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer : Early Toxicity Results from the Scandinavian Randomized Phase III Trial "HYPO-RT-PC" , 2016 .

[4]  D. Low,et al.  Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Nawrocki,et al.  SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer , 2016, Strahlentherapie und Onkologie.

[6]  J. Lynch,et al.  Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction , 2016, Front. Oncol..

[7]  T. Wiegel,et al.  Abstracts DEGRO 2017 , 2017, Strahlentherapie und Onkologie.

[8]  V. Rudat,et al.  Image-guided intensity-modulated radiotherapy of prostate cancer , 2015, Strahlentherapie und Onkologie.

[9]  Elena Villaggi,et al.  A feasibility dosimetric study on prostate cancer , 2015, Strahlentherapie und Onkologie.

[10]  B. Slotman,et al.  Roll and pitch set-up errors during volumetric modulated arc delivery , 2015, Strahlentherapie und Onkologie.

[11]  Sang Nam Lee,et al.  Stereotactic body radiotherapy for prostate cancer: A preliminary report , 2014, Asia-Pacific journal of clinical oncology.

[12]  John T. Wei,et al.  Comparative effectiveness of external-beam radiation approaches for prostate cancer. , 2014, European urology.

[13]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[14]  G. Andriole.  Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer , 2013 .

[15]  G. Lu-Yao.  Re: Radical Prostatectomy Versus Observation for Localized Prostate Cancer Wilt TJ, Brawer MK, Jones KM, et al., Prostate Cancer Intervention Versus Observation Trial (PIVOT) Study Group , 2013 .

[16]  I. Toma-Dasu,et al.  Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients , 2012, Acta oncologica.

[17]  M. Zelefsky,et al.  Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[18]  I. Kaplan,et al.  Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinoma , 2012, Cancer.

[19]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[20]  M. Frydenberg,et al.  Active surveillance for prostate cancer: an Australian experience , 2012, BJU international.

[21]  James D Brooks,et al.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[22]  A. Markoe,et al.  Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. , 2004, International journal of radiation oncology, biology, physics.

[23]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. , 2012, The Lancet. Oncology.

[24]  J. Hendry,et al.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. , 2012, International journal of radiation oncology, biology, physics.

[25]  M. Santoro,et al.  Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect? , 2011, Front. Oncol..

[26]  E. Oermann,et al.  Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy , 2011, Front. Oncol..

[27]  C. King.  Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. , 2011, Frontiers of radiation therapy and oncology.

[28]  Y. Yamada,et al.  Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancer , 2011, Cancer.

[29]  E. Oermann,et al.  Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer , 2011, Journal of hematology & oncology.

[30]  J. Fowler,et al.  Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[31]  I. Yeo,et al.  Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy , 2011, Journal of applied clinical medical physics.

[32]  L. Brady,et al.  Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer , 2011, American journal of clinical oncology.

[33]  C. King,et al.  Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes , 2011, Radiation oncology.

[34]  A. Katz.  CyberKnife Radiosurgery for Prostate Cancer , 2010, Technology in cancer research & treatment.

[35]  J. Deasy,et al.  Radiation dose-volume effects in radiation-induced rectal injury. , 2010, International journal of radiation oncology, biology, physics.

[36]  Lawrence B Marks,et al.  Radiation dose-volume effects of the urinary bladder. , 2010, International journal of radiation oncology, biology, physics.

[37]  C. Lawton,et al.  Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial , 2010 .

[38]  M. Yano,et al.  Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[39]  Lawrence B Marks,et al.  Regional lung density changes after radiation therapy for tumors in and around thorax. , 2010, International journal of radiation oncology, biology, physics.

[40]  Avid,et al.  INTRAFRACTIONAL MOTION OF THE PROSTATE DURING HYPOFRACTIONATED RADIOTHERAPY , 2009 .

[41]  M. Soloway,et al.  Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. , 2008, The Journal of urology.

[42]  Robert D Timmerman,et al.  An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. , 2008, Seminars in radiation oncology.

[43]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[44]  Haoran Jin,et al.  Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. , 2008, International journal of radiation oncology, biology, physics.

[45]  E. Chamorey,et al.  Radiothérapie robotisée des cancers de prostate par CyberKnife , 2007 .

[46]  J. Fowler,et al.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. , 2007, International journal of radiation oncology, biology, physics.

[47]  P. Bondiau,et al.  [Robotic radiotherapy for prostate cancer with CyberKnife]. , 2007, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[48]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  G. Naglie,et al.  30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. , 2005, Journal of the National Cancer Institute.

[50]  J. Fowler,et al.  The radiobiology of prostate cancer including new aspects of fractionated radiotherapy , 2005, Acta oncologica.

[51]  Hans Garmo,et al.  Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer , 2011 .

[52]  Juni Palmgren,et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.

[53]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[54]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[55]  D. Dearnaley,et al.  Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial , 1999, The Lancet.

[56]  Kathleen A. Moon,et al.  Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. , 1998, The Journal of urology.

[57]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[58]  P. Walsh,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. , 1997, The Journal of urology.

[59]  P. Walsh.  Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.

[60]  W. Catalona,et al.  Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. , 1993, The Journal of urology.

[61]  A. Stenwig,et al.  Prognosis of localised prostatic cancer managed by "watch and wait" policy. , 1993, British journal of urology.